The use of powerful weight-loss drugs is expanding access to healthcare services, particularly among patients with obesity-related conditions. A recent analysis of electronic patient records found that prescriptions for GLP-1 weight-loss drugs have led to a significant increase in diagnoses of sleep apnea, cardiovascular disease, and type 2 diabetes within 15 days.
According to the data, for every 1,000 patients prescribed GLP-1, 42 were diagnosed with type 2 diabetes, while 11 per 1,000 were diagnosed with sleep apnea. The most obese patients were twice as likely to receive a type 2 diabetes diagnosis and three times more likely to be diagnosed with sleep apnea.
These findings suggest that weight-loss drugs are becoming a tool for preventative care, allowing patients to access services such as organ transplants, fertility treatments, or knee replacements. “This is a population that previously felt stigmatized by healthcare providers,” said Dr. Rekha Kumar, an endocrinologist and obesity medicine specialist. “Now that they’re seeing themselves get healthier, asking clinicians questions, and engaging more, I do think we’re seeing new patients.”
The data also show that weight-loss drugs are being used to qualify for surgeries, such as joint replacements or organ transplants. A recent study found that the medications are bringing people into primary care like never before.
However, experts note that the impact of these weight-loss drugs on overall healthcare use is not yet clear. Andrew Friedson, director of health economics at the Milken Institute, said the new diagnoses could mean higher initial spending, but early detection could save costs down the line.
As patients gain confidence in their ability to make lifestyle changes and manage their conditions, they are becoming more proactive about seeking medical care and treatment options. This shift is helping to redefine the relationship between healthcare providers and patients with obesity-related conditions.
Source: https://www.reuters.com/business/healthcare-pharmaceuticals/weight-loss-drugs-draw-americans-back-doctor-2024-12-16